Expressions and clinical significances of paired box gene 2 and cyclin D1 in advanced ovarian serous carcinoma
10.3760/cma.j.issn.0253-3766.2017.12.003
- VernacularTitle: 配对盒基因2和细胞周期蛋白D1在晚期卵巢浆液性腺癌中的表达及临床意义
- Author:
Yan SONG
1
;
Jing ZUO
2
;
Xuan HUANG
1
;
Guihua SHEN
1
;
Xiuyun LIU
1
;
Xun ZHANG
1
Author Information
1. Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peiking Union Medical College, Beijing 100021, China
2. Department of Gynecology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peiking Union Medical College, Beijing 100021, China
- Publication Type:Clinical Trail
- Keywords:
Ovarian neoplasms;
Paired box genes 2;
Cyclin D1;
Immunohistochemistry;
Tissue microarray;
Prognosis
- From:
Chinese Journal of Oncology
2017;39(12):891-895
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expressions and clinical significances of paired box gene 2 (Pax2) and cyclin D1 protein in advanced ovarian serous carcinoma.
Methods:From January 2003 to December 2013, the pathologic tissues of 202 patients with advanced ovarian serous cancer (Ⅲ-Ⅳ) who underwent initial cytoreductive surgery were collected. The expressions of Pax2 and cyclin D1 protein were detected by immunohistochemistry in tissue microarray. The relationships of their expressions with the clinicopathological features and prognosis of the patients were analyzed.
Results:The positive rate of Pax2 protein expression of the 202 patients with ovarian serous adenocarcinoma was 24.8% (50/202) and that of cyclin D1 was 25.2% (51/202). The expressions of Pax2 and cyclin D1 were not significantly related with age, clinical stage and pathological grade of ovarian serous adenocarcinoma patients (P>0.05). The median overall survival (OS) time of Pax2-negative patients was 53 months and the progression-free survival (PFS) time was 29 months. The median OS time of Pax2-positive patients was 66 months and PFS time was 33 months, the OS of Pax2-negative patients was significant different from that of Pax2-positive patients (χ2=4.06, P=0.04). The median PFS time of Pax2-negative patients was not significant different from that of Pax2-positive patients (χ2=2.43, P=0.11). The median OS time of cyclin D1-negative patients was 62 months and PFS time was 30 months. The median OS time of cyclin D1-positive patients was 48 months and PFS time was 22 months. The median OS time of cyclin D1-negative patients was significantly different from that of cyclin D1-positive patients (χ2=4.71, P=0.03), while the median PFS time of cyclin D1-negative patients was marginally different from that of cyclin D1-positive patients (χ2=0.59, P=0.41). Multivariate analysis showed that the expression of Pax2 was an independent factor of the prognosis for patients with ovarian serous adenocarcinoma (RR=0.597, 95% CI 0.371-0.962, P<0.034).
Conclusion:The expressions of Pax2 and cyclin D1 are associated with the prognosis of patients with advanced ovarian serous adenocarcinoma while Pax2 is an independent prognostic factor.
